TTM2-TAME Trial

All Done!

A bit more to do?    Log in


The latest from the Spiral blog . . .

Win an iPad at the ANZICS Queenstown WRF 2019

2019-08-08

Spiral is going to the ANZICS-CTG Winter Research Forum in Queenstown!

We are very pleased and excited to support the ANZICS-CTG community and to attend the forum where we expect to learn more about the trials undertaken by the CTG.  Five of the trials listed on the program are, or will be, using the Spinnaker platform; these are Mega-ROX, Reactor, TARGET, TARGET Protein, and REMAP-CAP.

Cain and Audrey are looking forward to seeing you there!

... and look out for the competition - we will be giving away an iPad for the most relevant photo on Twitter. Competition details »

 
 

Follow us on Twitter

     
 

Like us on Facebook




 

About the TTM2 Study

The TTM2 trial is a phase III, multi-centre, randomized, parallel-group, clinical trial in resuscitated cardiac arrest patients admitted to the intensive care unit to investigate whether targeted temperature management (TTM) to 33°C improves survival and neurological outcome at 6 months compared to a strategy of targeting normothermia and avoiding fever above 37.7°C. More information »

About the TAME Study

The TAME trial is a phase III, multi-centre, randomised, parallel-group, clinical trial in resuscitated cardiac arrest patients admitted to the intensive care unit to determine whether targeted therapeutic mild hypercapnia (TTMH) improves neurological outcome at 6 months compared to standard care (targeted normocapnia) (TN). More information »

About the software

Spinnaker is a tailored, web based, software and database solution for managing your multi-centre clinical study including the recording of patient data, recording and alerting of events, inventory management and reporting on data collected during the course of your study. Spinnaker is user friendly, adaptable and can be delivered quickly. You can read more on the Spinnaker website or contact Audrey on spinnaker@spiral.co.nz.

 

You can get to know us a little better through our blog and social media pages accessed via the logout screen of this trial.